CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B

Erscheinungsjahr 2025
ISBN: 978-0-443-22420-1
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm

CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR -Cas systems for metabolic disorders, Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR -Cas systems for cataract and blindness, Advances in CRISPR -Cas systems for muscular dystrophy, Recent development in CRISPR -Cas systems for cardiac disease, Current approaches in CRISPR -Cas systems for diabetes, and much more.

Additional sections cover Advances in CRISPR -Cas systems for liver disease, Advances in CRISPR -Cas systems for lung disease, Advances in CRISPR -Cas systems for kidney diseases, Current progress in CRISPR -Cas systems for rare disease, Advances in CRISPR -Cas systems for heredity disease, Recent progress in CRISPR -Cas systems for neurological disorders, and CRISPR challenges in clinical developments.

Autoren/Hrsg.

Weitere Mitwirkende

Singh, Vijai

Fachgebiete

• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
• Naturwissenschaften Biowissenschaften Molekularbiologie

Inhaltsverzeichnis

Preface
Vijai Singh
1. Current approaches in CRISPR -Cas systems for metabolic disorders
DHRUV KUMAR
2. Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases
Mayank Bansal
3. Recent progress in CRISPR -Cas systems for cataract and blindness
Suresh Ramakrishna
4. Advances in CRISPR -Cas systems for muscular dystrophy
Vancha Harish
5. Recent development in CRISPR -Cas systems for cardiac disease
Xin Wang
6. Current approaches in CRISPR -Cas systems for diabetes
L. Karthik
7. Advances in CRISPR -Cas systems for liver disease
Majid Mojarrad
8. Advances in CRISPR -Cas systems for lung disease
Suresh Ramakrishna
9. Advances in CRISPR -Cas systems for kidney diseases
Anil Bhanudas Gaikwad
10. Current progress in CRISPR -Cas systems for rare disease
Ajay Kumar I
11. Advances in CRISPR -Cas systems for heredity disease
DHRUV KUMAR
12. Recent progress in CRISPR -Cas systems for neurological disorders
Anand Krishna Tiwari
13. CRISPR challenges in clinical developments
Hossein Soltaninejad, Mohadeseh Khoshandam and Saman Hosseinkhani

Über Autor(innen)

Singh, Vijai
Dr Vijai Singh is a Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Associate Professor in the Department of Biosciences, School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. Prior this this, he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 100 articles, 70 chapters, 15 books and 3 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.